Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Brain Neoplasms 7 Carcinoma, Renal Cell 4 Glioblastoma 3 Central Nervous System Neoplasms 3 Carcinoma, Medullary 3 Wilms Tumor 2 Sarcoma, Ewing 2 Sarcoma 2 Rhabdomyosarcoma 2 Pheochromocytoma 2 Paraganglioma 2 Osteosarcoma 2 Neurofibroma, Plexiform 2 Glioma 2 Astrocytoma 2 Triple Negative Breast Neoplasms 1 Thyroid Neoplasms 1 Thyroid Carcinoma, Anaplastic 1 Sarcoma, Clear Cell 1 Sarcoma, Alveolar Soft Part 1 Rhabdoid Tumor 1 Paraganglioma, Extra-Adrenal 1 Neurofibromatosis 1 1 Neurofibromatoses 1 Neuroendocrine Tumors 1 Neuroblastoma 1 Meningioma 1 Melanoma 1 Lung Neoplasms 1 Hepatoblastoma 1

Interventions

mirdametinib 3 Imatinib Mesylate 3 Surveys and Questionnaires 2 tipifarnib 1 talimogene laherparepvec 1 pirfenidone 1 nilotinib 1 emvododstat 1 diphenylcyclopropenone 1 cabozantinib 1 binimetinib 1 Sunitinib 1 Sirolimus 1 Sevoflurane 1 Propofol 1 Percutaneous Collagen Induction 1 Nitrous Oxide 1 Magnetic Resonance Spectroscopy 1 Lidocaine 1 Lasers, Solid-State 1 Lasers 1 Glycopyrrolate 1 Dexmedetomidine 1 Blood Specimen Collection 1 Aminolevulinic Acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Neurofibromatoses × cabozantinib × CNS × Clear all

NCT02101736 2023-05-24

NF105-CABO

University of Alabama at Birmingham

Phase 2 Completed

45 enrolled 10 charts

Neurofibromatoses, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon ⚡